|The Sexual Rehabilitation Unit of the Department of Urology provides
treatment for both men and women with sexual dysfunction.
Our highly trained staff consists of a senior urologist, a sexologist and a specialty-trained nurse.
The majority of our patients are those with risk factors of developing sexual disturbances from Diabetes Mellitus, Ischemic Heart Disease, Hypercholesterolemia and Endocrinology Disturbances.
We have strong ties to the hospital's rehabilitation staff and our team is brought in to treat patients with spinal cord injuries and other neurological disabilities such as stroke and Multiple Sclerosis.
In some cases the diagnosis is very clear and we communicate it to the patient in the first visit. In other cases, based on the initial evaluation, we refer the patient to a specialist in the field of Gynecology, Endocrinology, Psychiatry, or Sex Therapy.
If further diagnosis is needed, we perform additional tests to determine the best treatment. These tests include Nocturnal Penile Tumescence and Rigidity Test, vascular testing, and neurological testing.
Once a diagnosis is made, we treat patients through:
- Lifestyle adjustments: reducing alcohol consumption.
- Discontinuing use of smoking and other tobacco problems.
- Discontinuing use of recreational drugs.
- Keeping general health by reducing weight and doing exercise.
If medication is determined as the appropriate treatment, we offer first, second and third line therapy treatments. Our first line therapy treatments include:
- Natural treatments.
- Oral medications such as Viagra and other new drugs that are currently being tested such as: Cialis (Tadalafil),and Vardenafil
- Sublingual Apomorphine (Uprima)
- Vacuum Erection Therapy
Our second line therapy treatment consists of:
- Self Injection Therapy
- Intrauretheral Therapy - MUSE
- Topical gels and ointments
Our third line therapy treatment is Penile Implants, which are reserved for those who fail the other treatments.
Our unit takes a part in large multi country studies. We participated in the study on new drug approval for Cialis and Vardenafil. We also participated in a multi center study in Israel on patients that did not respond to Viagra treatment.
|Unit at a Glance |
| Number of Outpatient Visits per Year - 1,100|
Director - Dr. Gil Raviv
| Address - The Goldschleger Center for Advanced Technologies|
| E-mail - Gil.Raviv@sheba.health.gov.il|
| Tel - 972-3-530-4419|